Global Intravenous (IV) Iron Drugs Market Size | COVID-19 Impact Analysis | Forecast to 2028 

The market global intravenous (IV) iron drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Iron is one of the most essential elements which plays an important role in biological processes such as the syntheses of heme, energy metabolism, and immune system function. Iron deficiency is one of the major causes of iron deficiency anemia (IDA) that is associated with increased morbidity and mortality. Iron supplements are available in two forms, such as oral and intravenous. Intravenous iron preparations are superior to oral supplements, as this lead to higher and faster increases in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, and poor gastrointestinal absorption. An increase in the incidence of iron deficiency, a rise in chronic kidney disease patients who are undergoing dialysis, and a surging diabetic population are some of the major factors that are driving the growth of the market.

Scope of the Intravenous (IV) Iron Drugs Report

The research study analyzes the Intravenous (IV) Iron Drugs industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis

o Import and Export Overview

o Volume Analysis

o Current Market Trends and Future Outlook

o Market Opportunistic and Attractive Investment Segment

Intravenous (IV) Iron Drugs Market Segmentation:

By Type

• Ferric carboxymaltose
• Iron Sucrose
• Iron Dextran

By Application

• Nephrology
• Gynecology and Obstetrics
• Gastroenterology
• Oncology
• Cardiology

Some major companies in the market include Sanofi SA, AbbVie Inc. (Allergan plc), and Daiichi Sankyo Co., Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, Daiichi Sankyo Co., Ltd. announced the establishment of its wholly-owned subsidiary Daiichi Sankyo Vietnam Co. Ltd.

Geographic Coverage

o North America Market Size and/or Volume

o Latin America Market Size and/or Volume

o Europe Market Size and/or Volume

o Asia-Pacific Market Size and/or Volume

o Rest of the world Market Size and/or Volume

Key Questions Answered by Intravenous (IV) Iron Drugs Market Report

1. What was the Intravenous (IV) Iron Drugs Market size in 2021 and 2027; what are the estimated growth trends and market forecast (2022-2028).
2. What will be the CAGR of Intravenous (IV) Iron Drugs Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Intravenous (IV) Iron Drugs Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.

The report covers the following objectives:

• Proliferation and maturation of trade in the Intravenous (IV) Iron Drugs market.
• The market share of the Intravenous (IV) Iron Drugs market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the Intravenous (IV) Iron Drugs market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the Intravenous (IV) Iron Drugs market.